Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 52 points (0.3%) at 15,523 as of Thursday, Aug. 8, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,945 issues advancing vs. 956 declining with 122 unchanged. The Health Care sector currently sits down 0.7% versus the S&P 500, which is up 0.4%. Top gainers within the sector include DexCom ( DXCM), up 25.0%, ResMed ( RMD), up 3.3%, Valeant Pharmaceuticals International ( VRX), up 2.3%, HCA Holdings ( HCA), up 1.7% and Boston Scientific ( BSX), up 1.6%. On the negative front, top decliners within the sector include Amgen ( AMGN), down 1.5%, and Pfizer ( PFE), down 0.7%. TheStreet would like to highlight 5 stocks pushing the sector higher today: 5. Sanofi ( SNY) is one of the companies pushing the Health Care sector higher today. As of noon trading, Sanofi is up $0.42 (0.8%) to $52.70 on heavy volume. Thus far, 1.8 million shares of Sanofi exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $52.41-$52.99 after having opened the day at $52.90 as compared to the previous trading day's close of $52.28. Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $138.0 billion and is part of the drugs industry. Shares are up 10.3% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.